aTyr Pharma has reported that the US Patent office has issued patent US no 7572452 B2, titled ‘Method for Stimulating Wound Healing’.
Reportedly, this patent covers new extracellular activities for p43, a critical protein component of the multi-aminoacyl tRNA synthetase complex in humans.
The aminoacyl tRNA synthetases are universal and essential elements of the protein synthesis machinery found in all organisms, but human synthetases and their associated proteins have naturally occurring resected variants, called resectins, with potent cell signaling activities that are vital to normal functioning of humans.
Jeff Watkins, CEO of aTyr Pharma, said: “This patent covers discoveries Professor Kim has made for extracellular activity of the p43 component of the multi-sythetase complex. Capitalising on this new area of biology, we are identifying and developing these naturally occurring resectins as candidate biotherapeutics for treating a wide variety of diseases.”